| Literature DB >> 30704657 |
Srikala Yedavally-Yellayi1, Andrew Manyin Ho2, Erwin Matthew Patalinghug2.
Abstract
Osteoporosis is often a silent disease that reveals itself at the time of a fracture. Assessing risk factors and applying appropriate screening guidelines in the population at risk can potentially decrease the looming high disease burden in the United States. FRAX is a validated tool that can be used to determine 10-year fracture risk to assist in medical decision making. Bone mineral density testing of the hip or spine using DEXA can be used alone or in combination with FRAX to determine patients' risk for fracture and determine if patients are candidates for treatment of osteoporosis.Entities:
Keywords: Bisphosphonates; Bone mineral density; DEXA; Low bone mass; Osteoporosis; Screening
Mesh:
Year: 2018 PMID: 30704657 DOI: 10.1016/j.pop.2018.10.014
Source DB: PubMed Journal: Prim Care ISSN: 0095-4543 Impact factor: 2.907